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Abstract
Introduction The prevalence of sleep breathing disorders
in patients with congestive heart failure is relevantly
high. According to historical studies Cheyne–Stokes
respiration is an oscillatory ventilation during sleep in
up to 40% of patients with congestive heart failure.
During the last decade the medical treatment of conges-
tive heart failure has been improved. The aim of this
investigation was to analyze the prevalence of Cheyne–
Stokes respiration in patients with congestive heart failure
and modern medical treatment.
Results and discussion In 50 patients with severe conges-
tive heart failure receiving modern medical treatment a
full night polysomnography was performed. All patients
had ß-blockers and angiotensin-converting-enzyme inhib-
itors or angiotensin-II-antagonists as standard treatment.
The mean age was 63±12 years and the mean left
ventricular ejection fraction was 26±6%. Respiratory
polygraphy revealed Cheyne–Stokes respiration with a
respiratory disturbance index of ≥5/h sleep in 32 (64%)
of the seven female and 43 male patients. The prevalence
of Cheyne–Stokes respiration defined by using the
threshold of an apnea index of ≥10/h was 30%.
Conclusion Thus, no significant change of Cheyne–Stokes
prevalence could be found in our modern treated severe
congestive heart failure collective.
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Introduction
For a number of years a high prevalence of sleep breathing
disorders has been known to exist in patients with
congestive heart failure [1–3]. Congestive heart failure is
one of the leading causes of morbidity and mortality in
developed countries. Since the description of a waxing and
waning breathing pattern by Cheyne and Stokes the
occurrence of Cheyne–Stokes respiration is well-recognized
in congestive heart failure [4–5]. Several investigators
showed an increased mortality in congestive heart failure
combined with Cheyne–Stokes respiration [6, 7]. This
possibly results from increased neurohumoral stress on the
heart [8]. The treatment of congestive heart failure patients
has changed during the last decade when new therapeutic
standards like beta-blockers and angiotensin-converting-
enzyme inhibitors have been established [9]. Prognosis of
congestive heart failure patients has been improved by
these new treatment standards.
The aim of this study was to find out if modern medical
treatment has diminished sleep disordered breathing like
Cheyne–Stokes respiration in congestive heart failure
patients.
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All patients with severe heart failure enrolled in the study
of the Department of Cardiology at University Hospital
were eligible if they met the following criteria: a left
ventricular ejection fraction of ≤35% and at least one
episode of cardiac decompensation in patient history.
They all had to be in stable cardiac conditions at NYHA-
classification class 2–3 and had to have a beta-blocker
and an angiotensin-converting-enzyme inhibitor or an
angiotensin-II-antagonist as standard medications. No
primary lung dysfunction with a forced expiratory
volume in 1 s <65% was accepted for participants and
no myocardial infarction should have been in the last
6 months. The patients had to be at a minimum age of
18 years. For recruitment the consecutive patients were
primarily screened by echocardiographic ejection fraction
and then the other criteria had to be fulfilled.
All patients provided informed consent to participate in
the study, which was performed in accordance with the
principles of the Declaration of Helsinki and approved by
the ethics committee at the University of Goettingen. Each
patient had to have a pulmonary function test as well as an
electrocardiography and echocardiography.
Polysomnography was performed in one night at the
sleep laboratory of the cardiology and pneumology depart-
ment. No patient had a known history of sleep disordered
breathing prior to our investigations. To determine the
stages of sleep an electroencephalogram, a chin electro-
myogram and an electrooculogram were obtained. Thor-
acoabdominal excursions were measured with strain gauges
placed on the rib cage and abdomen. Airflow was
monitored with thermocouples. All polysomnographic data
were collected by computer system (Alice 4, Heinen &
Löwenstein, Germany). According to the manual criteria of
the American Academy of Sleep Medicine there had to be at
least three cycles of crescendo and decrescendo change in
breathing amplitude and five or more central sleep apneas or
hypopneas per hour of sleep to be scored as Cheyne–Stokes
respiration [10]. Furthermore according to the international
classification of sleep disorders (ICSD-2) the apnea index
(AI) of ≥10/h was defined as relevant [11]. In all patients
classified as having obstructive sleep apnea or Cheyne–
Stokes respiration, that breathing disorder was the predom-
inant pattern. Obstructive apnea or hypopnea was defined
as an absence or a reduction of airflow for at least 10 s
despite continued out-of-phase chest and abdominal move-
ments. A mixed apnea was defined as an apnea with a
combination of both central and obstructive components.
Statistical analysis was performed with SPSS (SPSS
GmbH Software, Germany). The Mann–Whitney test was
used to assess differences between patients with and
without sleep disordered breathing, and chi-square anal-
ysis was used to analyze proportions. A two-sided P
value of less than 0.05 was considered to indicate statistical
significance. Values are reported as means.
Results
Fifty patients were included in the study (Table 1). Four
of the six female and 22 of the 44 male patients had
ischemic cardiomyopathy. Twenty patients had a dilated
and four a hypertrophic nonobstructive cardiomyopathy.
Sinus rhythm has been registered in 39 patients and arterial
hypertension was prevalent in 31 patients. A documented
diabetes mellitus has been observed in 14 patients, as often
as nicotine abuse. More often the cardiac risk factor of
hyperlipidemia were seen with 30 patients.
All of the patients were being treated with a beta-blocker-
medication and 42 were treated with angiotensin-converting-
enzyme inhibitor while eight had angiotensin-II-antagonists.
All patients were being treated with diuretic medications and
12 with digitalis. Eighteen patients received an aldosteron
antagonist.
According to the mentioned American Academy of Sleep
Medicine (AASM)-manual-criteria there were eight patients
with a respiratory disturbance index (RDI) of less than 5/h and
64% of all study patients had Cheyne–Stokes breathing
patterns (Table 2). Twenty-two (44%) of all patients had a
Cheyne–Stokes respiration with an AHI >15/h. Ten patients
(20%) had mainly obstructive sleep breathing disorders
during sleep.
If ICSD-2-criteria for sleep investigations were used there
would have been 34 patients (68%) with an AI of less than
10/h. Fifteen (30%) of all patients had a Cheyne–Stokes
respiration with an AI ≥10/h (25±13 vs 4±10, p<0.0001).
Considering cardiac characteristics of all patients the
mean ejection fraction was 26±6% and the average left
ventricular diastolic dimension was 64±8 mm. Mean septal
dimension was 11±2 mm and left atrial dimension was 49±
8 mm. Divided into patient groups with and without








Age (years) 63±12 62±13 63±12 ns
Body mass index (kg/m2) 26.6±4.3 26.3±3.7 27.1±5.3 ns
Height (cm) 175±10 177±9 172±10 0.1
Heart rate (bpm) 74±18 75±18 70±18 ns
FEV1/VC (% standard) 102±16 102±14 101±19 ns
CSR patients with Cheyne–Stokes respiration according to AASM-
manual-criteria, NCSR non Cheyne–Stokes respiration patients, ns
non-significant, FEV1/VC %Standard forced exspiratory volume in 1
second/vitalcapacity in percent of standard value
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Cheyne–Stokes respiration according to AASM-manual-
criteria the only significant difference was the septal
dimension regardless of the kind of sleep disorders cutoff
point (Table 3). For ICSD-2-criteria there was a tendency to
a worse ejection fraction in patients suffering from Cheyne–
Stokes respiration (p<0.1).
Discussion
Cheyne–Stokes respiration has been common during sleep
in congestive heart failure patients in previously published
investigations [1–3, 12]. There are also hints for a poorer
prognosis in those congestive heart failure patients with
Cheyne–Stokes respiration [6, 7, 13]. Modern medical
treatment has a prognostic impact in patients with conges-
tive heart failure [14–19]. In a small study population of
8 patients Walsh and colleagues showed a reduction of
apneic episodes as well as arousals and an increase of slow
wave and REM sleep by treatment with captopril [20].
More recent studies by Koehnlein and colleagues as well as
Tamura and colleagues stated a reduced prevalence in
ß-blocker-treated heart failure patients [21, 22]. Both
investigations failed to request equal baseline therapy
according to treatment guidelines.
In this investigation modern medication standards like
beta-blockers and angiotensin-converting-enzyme inhibi-
tors or angiotensin-II-antagonists showed no beneficial
influence in the prevalence of Cheyne–Stokes respiration.
As a limitation no own control data were used.
While there are widely accepted standards for analyses
of sleep apnea the definition of Cheyne–Stokes respiration
is less precise. If the actual AASM-manual-criteria of sleep
breathing disorders with a cutoff respiratory disturbance
index of ≥5/h would have been used, the incidence would
be 64%. These results are almost similar to the retrospective
study results of Sin et al. in 450 patients with an occurrence
of sleep breathing disorders of 72%, 61%, and 53%
according to an apnea–hypopnea index cutoff point of 10,
15, and 20/h in congestive heart failure patients [3]. Still in
that earlier study no standard medical treatment was given as
recommended by modern heart failure treatment guidelines
[9]. As the respiratory disturbance index is attributed to the
total sleep time [23], it tends to be higher than the apnea–
hypopnea index related to the total recording time in bed [7].
This termination has not been standardized so far, therefore
an apnea–hypopnea index could have been related to time-
in-bed or total sleep time in earlier investigations [2, 7, 24].
Furthermore the ICSD-2 definitions recommend an AI ≥10/
h for Cheyne–Stokes respiration [11]. According to this
definition there would be a lower number of patients with
Cheyne–Stokes respiration in our study population, still this
definition would not be comparable to previous studies.
In 203 German patients with congestive heart failure and
left ventricular ejection fraction <40% an apnea–hypopnea
index cutoff about 10/h were seen by polysomnography in
71% with a majority in obstructive sleep apnea probably due
to higher body mass index [25]. The prevalence of sleep
breathing disorders according to common study criteria with
an apnea–hypopnea index cutoff about 10/h and 15/h is
approximately 56% and 48% in our study population. The
prevalence in the historic collective of Javaheri et al. with an
apnea–hypopnea index cutoff about 15/h has been about
50% for sleep breathing disorders [2].
Compared to the prevalence in the study population of
Javaheri et al. the prevalence of Cheyne–Stokes respiration in
the sleep breathing disorders was between 66% and 44% in our
patients group depending on the cutoff versus 40% in
Javaheri’s patient group. The different inclusion criteria con-
cerning the ejection fraction of <45% in Javaheris study and
≤35% in our study may be the reason for the small difference.
A retrospective analyses in 450 consecutive patients with
congestive heart failure with an apnea–hypopnea index cutoff
about 10/h found a prevalence of sleep breathing disorders of
72% [3]. In that retrospective analyses the prevalence of
Cheyne–Stokes respiration of 33% was comparable to the
Table 3 Cardiac characteristics of the patients
Variable CSR (n=32) Non-CSR (n=18) P value
Ejection fraction (%) 26.3±6.3 25.8±6.7 ns
LVEDD (mm) 65.1±8.0 61.4±8.4 ns
Left atrial dimension (mm) 50.1±8.0 48.2±7.9 ns
Septal dimension (mm) 11.9±2.3 10.6±1.9 <0.05
Remained sinus rhythm 24 15 ns
Bundle brunch block 17 11 ns
CSR patients with Cheyne–Stokes respiration according to AASM-
manual-criteria, Non-CSR non Cheyne–Stokes respiration patients,
LVEDD left ventricular enddiastolic dimension, ns non-significant
Table 2 Characteristics of the patients during sleep
Variable CSR (n=32) NCSR (n=18) P value
Total sleep time (min) 314±62 297±100 ns
NonREM (min) 280±55 254±79 ns
REM (min) 50±29 53±28 ns
RDI (/h TST) 26±16 10±14 0.001
AHI (/h) 23±15 8±14 0.001
Apnea-index (/h sleep) 13±14 5±14 0.04
Arousal-index (/h sleep) 25±15 29±17 ns
Mean oxygen saturation (%) 89±4 90±3 ns
Min. oxygen saturation (%) 81±7 84±8 ns
CSR patients with Cheyne–Stokes respiration according to AASM-
manual-criteria, NCSR non Cheyne–Stokes respiration patients, TST
total sleep time, REM rapid eye movement sleep, RDI respiratory
disturbance index, AHI apnea-hypopnea index, ns non-significant
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German patients with 28% [25]. The differences to our as
well as Javaheris findings are possibly related to a higher
body mass index leading to an increased prevalence of
obstructive sleep apneas as well as no predefined inclusion
ejection fraction in Sins’ patient collective.
Although the modern medical treatment improved
prognostic outcome in congestive heart failure there
appears to be no clear evidence of a reduction in Cheyne–
Stokes respiration. The increasing prevalence of chronic
heart failure is affecting patients' quality of life, and health
resources, despite advances in management. Recognizing
and treating comorbid illnesses is critical. Risk factors such
as hypertension and diabetes are treated, but less impor-
tance is placed on the role of sleep apnea in heart failure.
Apneic episodes during sleep can lead to profound
disturbances to the sympathetic and parasympathetic ner-
vous system.
Conclusions
In conclusion special therapeutic strategies in Cheyne–Stokes
respiration may still be of importance for further prognostic
benefit in congestive heart failure patients. There is no clear
evidence for a reduction of Cheyne–Stokes respiration due to
modern medical treatment in congestive heart failure.
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